Frontotemporal demetia

Current Neurology and Neuroscience Reports

Volumn 6, Issue 6, 2006, Pages 481-489

  Roberson, Erik D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; CHOLINESTERASE INHIBITOR; METHYLPHENIDATE; PRESENILIN 1; PROGRANULIN; SEROTONIN UPTAKE INHIBITOR; TAU PROTEIN;

APHASIA; BRAIN ATROPHY; CLINICAL FEATURE; DIAGNOSTIC IMAGING; DISEASE MODEL; FRONTOTEMPORAL DEMENTIA; HISTOPATHOLOGY; HUMAN; LANGUAGE DISABILITY; NONHUMAN; PATHOPHYSIOLOGY; PICK PRESENILE DEMENTIA; PREDICTION; REVIEW; SPEECH DISORDER; SPEECH THERAPY; SYNDROME; TAUOPATHY; DEMENTIA; GENETICS; PATHOLOGY;

DEMENTIA; HUMANS;

EID: 33751011026     PISSN: 15284042     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11910-006-0050-7     Document Type: Review

References (120)

1. Pick A: Über die Beziehungen der sinilen Hirnatrophie zur Apbasie. Prag Med Wochenschr 1892, 17:165-167.
2. Alzheimer A: Über eine eigenartige Erkrankung der Hirnrinde. Allgemeine Zeitschrift für Psychiatrie und Psychisch-Gerichtliche Medizine 1907, 34:146-148.
3. Clinical and neuropathological criteria for frontotemporal dementia. The Lund and Manchester Groups. J Neurol Neurosurg Psychiatry 1994, 57:416-418.
4. Neary D, Snowden JS, Gustafson L, et al.: Frontotemporal lobar degeneration: A consensus on clinical diagnostic criteria. Neurology 1998, 51:1546-1554.
5. Ratnavalli E, Brayne C, Dawson K, Hodges JR: The prevalence of frontotemporal dementia. Neurology 2002, 58:1615-1621.
6. Kertesz A, McMonagle P, Blair M, et al.: The evolution and pathology of frontotemporal dementia. Brain 2005, 128:1996-2005.
7. Kertesz A, Munoz D: Pick's disease, frontotemporal dementia, and Pick complex: Emerging concepts. Arch Neurol 1998, 55:302-304.
8. Miller BL, Darby A, Benson DF, et al.: Aggressive, socially disruptive and antisocial behaviour associated with frontotemporal dementia. Br J Psychiatry 1997, 170:150-154.
9. Miller BL, Seeley WW, Mychack P, et al.: Neuroanatomy of the self: evidence from patients with frontotemporal dementia. Neurology 2001, 57:817-821.
10. Miller BL, Darby AL, Swartz JR, et al.: Dietary changes, compulsions and sexual behavior in frontotemporal degeneration. Dementia 1995, 6:195-199.
11. Knibb JA, Hodges JR: Semantic dementia and primary progressive aphasia: A problem of categorization? Alzheimer Dis Assoc Disord 2005, 19(Suppl 1):S7-S14.
12. Snowden JS: Semantic dysfunction in frontotemporal lobar degeneration. Dement Geriatr Cogn Disord 1999, 10(Suppl 1):33-36.
13. Strong MJ, Lomen-Hoerth C, Caselli RJ, et al.: Cognitive impairment, frontotemporal dementia, and the motor neuron diseases. Ann Neurol 2003, 54(Suppl 5):S20-S23.
14. Goldman JS, Farmer JM, Wood EM, et al.: Comparison of family histories in FTLD subtypes and related tauopathies. Neurology 2005, 65:1817-1819.
15. Lomen-Hoerth C, Anderson T, Miller B: The overlap of amyotrophic lateral sclerosis and frontotemporal dementia. Neurology 2002, 59:1077-1079.
16. Roberson ED, Hesse JH, Rose KD, et al.: Frontotemporal dementia progresses to death faster than Alzheimer disease. Neurology 2005, 65:719-725.
17. Lomen-Hoerth C, Murphy J, Langmore S, et al.: Are amyotrophic lateral sclerosis patients cognitively normal? Neurology 2003, 60:1094-1097.
18. Rebeiz JJ, Kolodny EH, Richardson EP: Corticodentatonigral degeneration with neuronal achromasia. Arch Neurol 1968, 18:20-33.
19. Josephs KA, Petersen RC, Knopman DS, et al.: Clinicopathologic analysis of frontotemporal and corticobasal degenerations and PSP. Neurology 2006, 66:41-48.
20. Boeve BF, Maraganore DM, Parisi JE, et al.: Pathologic heterogeneity in clinically diagnosed corticobasal degeneration. Neurology 1999, 53:795-800.
21. Steele JC, Richardson JC, Olszewski J: Progressive supranuclear palsy. Arch Neurol 1964, 10:333-359.
22. Rampello L, Butta V, Raffaele R, et al.: Progressive supranuclear palsy: a systematic review. Neurobiol Dis 2005, 20:179-186.
23. Rosen HJ, Gorno-Tempini ML, Goldman WP, et al.: Patterns of brain atrophy in frontotemporal dementia and semantic dementia. Neurology 2002, 58:198-208.
24. Gorno-Tempini ML, Dronkers NF, Rankin KP, et al.: Cognition and anatomy in three variants of primary progressive aphasia. Ann Neurol 2004, 55:335-346.
25. Mummery CJ, Patterson K, Price CJ, et al.: A voxel-based morphometry study of semantic dementia: relationship between temporal lobe atrophy and semantic memory. Ann Neurol 2000, 47:36-45.
26. Seeley WW, Bauer AM, Miller BL, et al.: The natural history of temporal variant frontotemporal dementia. Neurology 2005, 64:1384-1390.
27. Klunk WE, Engler H, Nordberg A, et al.: Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004, 55:306-319.
28. Huey ED, Putnam KT, Grafman J: A systematic review of neurotransmitter deficits and treatments in frontotemporal dementia. Neurology 2006, 66:17-22.
29. Deakin JB, Rahman S, Nestor PJ, et al.: Paroxetine does not improve symptoms and impairs cognition in frontotemporal dementia: a double-blind randomized controlled trial. Psychopharmacology (Berl) 2004, 172:400-408.
30. Rahman S, Robbins TW, Hodges JR, et al.: Methylphenidate ('Ritalin') can ameliorate abnormal risk-taking behavior in the frontal variant of frontotemporal dementia. Neuropsychopharmacology 2006, 31:651-658.
31. de Vugt ME, Riedijk SR, Aalten P, et al.: Impact of behavioural problems on spousal caregivers: a comparison between alzheimer's disease and frontotemporal dementia. Dement Geriatr Cogn Disord 2006, 22:35-41.
32. NIH: http://www.clinicaltrials.gov. Accessed July 5, 2006.
33. Kril JJ, Macdonald V, Patel S, et al.: Distribution of brain atrophy in behavioral variant frontotemporal dementia. J Neurol Sci 2005, 232:83-90.
34. Broe M, Hodges JR, Schofield E, et al.: Staging disease severity in pathologically confirmed cases of frontotemporal dementia. Neurology 2003, 60:1005-1011.
35. Munoz DG, Dickson DW, Bergeron C, et al.: The neuropathology and biochemistry of frontotemporal dementia. Ann Neurol 2003, 54(Suppl 5):S24-S28.
36. Taniguchi S, McDonagh AM, Pickering-Brown SM, et al.: The neuropathology of frontotemporal lobar degeneration with respect to the cytological and biochemical characteristics of tau protein. Neuropathol Appl Neurobiol 2004, 30:1-18.
37. Su JH, Nichol KE, Sitch T, et al.: DNA damage and activated caspase-3 expression in neurons and astrocytes: evidence for apoptosis in frontotemporal dementia. Exp Neurol 2000, 163:9-19.
38. Martin JA, Craft DK, Su JH, et al.: Astrocytes degenerate in frontotemporal dementia: Possible relation to hypoperfusion. Neurobiol Aging 2001, 22:195-207.
39. Broe M, Kril J, Halliday GM: Astrocytic degeneration relates to the severity of disease in frontotemporal dementia. Brain 2004, 127:2214-2220.
40. Schofield E, Kersaitis C, Shepherd CE, et al.: Severity of gliosis in Pick's disease and frontotemporal lobar degeneration: tau-positive glia differentiate these disorders. Brain 2003, 126:827-840.
41. Goedert M, Spillantini MG, Potier MC, et al.: Cloning and sequencing of the cDNA encoding an isoform of microtubule-associated protein tau containing four tandem repeats: differential expression of tau protein mRNAs in human brain. EMBO J 1989, 8:393-399.
42. Delacourte A, Sergeant N, Wattez A, et al.: Vulnerable neuronal subsets in Alzheimer's and Pick's disease are distinguished by their tau isoform distribution and phosphorylation. Ann Neurol 1998, 43:193-204.
43. Hof PR, Bouras C, Perl DP, Morrison JH: Quantitative neuropathologic analysis of Pick's disease cases: cortical distribution of Pick bodies and coexistence with Alzheimer's disease. Acta Neuropathol (Berl) 1994, 87:115-124.
44. Probst A, Tolnay M, Langui D, et al.: Pick's disease: hyperphosphorylated tau protein segregates to the somatoaxonal compartment. Acta Neuropathol (Berl) 1996, 92:588-596.
45. Feany MB, Dickson DW: Widespread cytoskeletal pathology characterizes corticobasal degeneration. Am J Pathol 1995, 146:1388-1396.
46. Forman MS, Zhukareva V, Bergeron C, et al.: Signature tau neuropathology in gray and white matter of corticobasal degeneration. Am J Pathol 2002, 160:2045-2053.
47. Sergeant N, Wattez A, Delacourte A: Neurofibrillary degeneration in progressive supranuclear palsy and corticobasal degeneration: Tau pathologies with exclusively "Exon 10" isoforms. J Neurochem 1999, 72:1243-1249.
48. Dickson DW: Neuropathologic differentiation of progressive supranuclear palsy and corticobasal degeneration. J Neurol 1999, 246(Suppl 2):II6-II15.
49. Tolnay M, Clavaguera F: Argyrophilic grain disease: A late-onset dementia with distinctive features among tauopathies. Neuropathology 2004, 24:269-283.
50. Martinez-Lage P, Munoz DG: Prevalence and disease associations of argyrophilic grains of Braak. J Neuropathol Exp Neurol 1997, 56:157-164.
51. Neumann M, Sampathu DM, Kwong LK, et al.: Ubiquinated TDP-43 in frontotemporal lobal degeneration and amyotrophic lateral sclerosis. Science 2006, In press.
52. Jackson M, Lennox G, Lowe J: Motor neurone disease-inclusion dementia. Neurodegeneration 1996, 5:339-350.
53. Josephs KA, Holton JL, Rossor MN, et al.: Neurofilament inclusion body disease: A new proteinopathy? Brain 2003, 126:2291-2303.
54. Cairns NJ, Grossman M, Arnold SE, et al.: Clinical and neuropathologic variation in neuronal intermediate filament inclusion disease. Neurology 2004, 63:1376-1384.
55. Woulfe J, Kertesz A, Munoz DG: Frontotemporal dementia with ubiquitinated cytoplasmic and intranuclear inclusions. Acta Neuropathol (Berl) 2001, 102:94-102.
56. Rosso SM, Kamphorst W, de Graaf B, et al.: Familial frontotemporal dementia with ubiquitin-positive inclusions is linked to chromosome 17q21-22. Brain 2001, 124:1948-1957.
57. Kersaitis C, Halliday GM, Kril JJ: Regional and cellular pathology in frontotemporal dementia: Relationship to stage of disease in cases with and without Pick bodies. Acta Neuropathol (Berl) 2004, 108:515-523.
58. Kersaitis C, Halliday GM, Xuereb JH, et al.: Ubiquitin-positive inclusions and progression of pathology in frontotemporal dementia and motor neurone disease identifies a group with mainly early pathology. Neuropathol Appl Neurobiol 2006, 32:83-91.
59. Hodges JR, Davies RR, Xuereb JH, et al.: Clinicopathological correlates in frontotemporal dementia. Ann Neurol 2004, 56:399-406.
60. Shi J, Shaw CL, Du Plessis D, et al.: Histopathological changes underlying frontotemporal lobar degeneration with clinicopathological correlation. Acta Neuropathol (Berl) 2005, 110:501-512.
61. Forman MS, Farmer J, Johnson JK, et al.: Frontotemporal dementia: clinicopathological correlations. Ann Neurol 2006, 59:952-962.
62. Davies RR, Hodges JR, Kril JJ, et al.: The pathological basis of semantic dementia. Brain 2005, 128:1984-1995.
63. Knibb JA, Xuereb JH, Patterson K, Hodges JR: Clinical and pathological characterization of progressive aphasia. Ann Neurol 2006, 59:156-165.
64. Josephs KA, Duffy JR, Strand EA, et al.: Clinicopathological and imaging correlates of progressive aphasia and apraxia of speech. Brain 2006, 129:1385-1398.
65. Stevens M, van Duijn CM, Kamphorst W, et al.: Familial aggregation in frontotemporal dementia. Neurology 1998, 50:1541-1545.
66. Chow TW, Miller BL, Hayashi VN, Geschwind DH: Inheritance of frontotemporal dementia. Arch Neurol 1999, 56:817-822.
67. Grasbeck A, Horstmann V, Nilsson K, et al.: Dementia in first-degree relatives of patients with frontotemporal dementia. A family history study. Dement Geriatr Cogn Disord 2005, 19:145-153.
68. Hutton M, Lendon CL, Rizzu P, et al.: Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 1998, 393:702-705.
69. Poorkaj P, Bird TD, Wijsman E, et al.: Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann Neurol 1998, 43:815-825.
70. Spillantini MG, Murrell JR, Goedert M, et al.: Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc Natl Acad Sci USA 1998, 95:7737-7741.
71. Clark LN, Poorkaj P, Wszolek Z, et al.: Pathogenic implications of mutations in the tau gene in pallido-pontonigral degeneration and related neurodegenerative disorders linked to chromosome 17. Proc Natl Acad Sci USA 1998, 95:13103-13107.
72. Gass J, Cannon A, Mackenzie IR, et al.: Mutations in progranulin are a major cause of ubiqutin-positive frontotemporal lobar degeneration. Hum Mol Genet 2006, In press.
73. Wilhelmsen KC, Lynch T, Pavlou E, et al.: Localization of disinhibition-dementia-parkinsonism-amyotrophy complex to 17q21-22. Am J Hum Genet 1994, 55:1159-1165.
74. Cruts M, Rademakers R: Alzheimer Disease & Frontotemporal Dementia Mutation Database. http://www.molgen.ua.ac.be/ADMutations/default.cfm. Accessed June 15, 2006.
75. Goedert M, Jakes R: Mutations causing neurodegenerative tauopathies. Biochim Biophys Acta 2005, 1739:240-250.
76. Rademakers R, Cruts M, van Broeckhoven C: The role of tau (MAPT) in frontotemporal dementia and related tauopathies. Hum Mutat 2004, 24:277-295.
77. Sobrido MJ, Miller BL, Havlioglu N, et al.: Novel tau polymorphisms, tau haplotypes, and splicing in familial and sporadic frontotemporal dementia. Arch Neurol 2003, 60:698-702.
78. Rosso SM, Donker Kaat L, Baks T, et al.: Frontotemporal dementia in The Netherlands: Patient characteristics and prevalence estimates from a population-based study. Brain 2003, 126:2016-2022.
79. Baker M, Litvan I, Houlden H, et al.: Association of an extended haplotype in the tau gene with progressive supranuclear palsy. Hum Mol Genet 1999, 8:711-715.
80. Stefansson H, Helgason A, Thorleifsson G, et al.: A common inversion under selection in Europeans. Nat Genet 2005, 37:129-137.
81. Cruts M, Rademakers R, Gijselinck I, et al.: Genomic architecture of human 17q21 linked to frontotemporal dementia uncovers a highly homologous family of low-copy repeats in the tau region. Hum Mol Genet 2005, 14:1753-1762.
82. Di Maria E, Tabaton M, Vigo T, et al.: Corticobasal degeneration shares a common genetic background with progressive supranuclear palsy. Ann Neurol 2000, 47:374-377.
83. Rademakers R, Melquist S, Cruts M, et al.: High-density SNP haplotyping suggests altered regulation of tan gene expression in progressive supranuclear palsy. Hum Mol Genet 2005, 14:3281-3292.
84. Kwok JB, Teber ET, Loy C, et al.: Tau haplotypes regulate transcription and are associated with Parkinson's disease. Ann Neurol 2004, 55:329-334.
85. Kertesz A, Kawarai T, Rogaeva E, et al.: Familial frontotemporal dementia with ubiquitin-positive, tau-negative inclusions. Neurology 2000, 54:818-827.
86. Kwok JB, Teber ET, Loy C, et al.: Tau haplotypes regulate transscription and are associated with Parkinson's disease. Ann Neurol 2004, 55:329-334.
87. Baker M, Mackenzie IR, Pickering-Brown SM, et al.: Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature 2006, In press.
88. Cruts M, Gijselinck I, van der Zee J, et al.: Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature 2006, In press.
89. Kovach MJ, Waggoner B, Leal SM, et al.: Clinical delineation and localization to chromosome 9p13.3-p12 of a unique dominant disorder in four families: hereditary inclusion body myopathy, Paget disease of bone, and frontotemporal dementia. Mol Genet Metab 2001, 74:458-475.
90. Kimonis VE, Watts GD: Autosomal dominant inclusion body myopathy, Paget disease of bone, and frontotemporal dementia. Alzheimer Dis Assoc Disord 2005, 19 (Suppl 1): S44-S47.
91. Schröder R, Watts GD, Mehta SG, et al.: Mutant valosin-containing protein causes a novel type of frontotemporal dementia. Ann Neurol 2005, 57:457-461.
92. Forman MS, Mackenzie IR, Cairns NJ, et al.: Novel ubiquitin neuropathology in frontotemporal dementia with valosin-containing protein gene mutations. J Neuropathol Exp Neurol 2006, 65:571-581.
93. Watts GD, Wymer J, Kovach MJ, et al.: Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nat Genet 2004, 36:377-381.
94. Sauer RT, Bolon DN, Burton BM, et al.: Sculpting the proteome with AAA(+) proteases and disassembly machines. Cell 2004, 119:9-18.
95. Weihl CC, Dalal S, Pestronk A, Hanson PI: Inclusion body myopathy-associated mutations in p97/VCP impair endoplasmic reticulum-associated degradation. Hum Mol Genet 2006, 15:189-199.
96. Mizuno Y, Hori S, Kakizuka A, Okamoto K: Vacuole-creating protein in neurodegenerative diseases in humans. Neurosci Lett 2003, 343:77-80.
97. Brown J, Ashworth A, Gydesen S, et al.: Familial non-specific dementia maps to chromosome 3. Hum Mol Genet 1995, 4:1625-1628.
98. Gydesen S, Brown JM, Brun A, et al.: Chromosome 3 linked frontotemporal dementia (FTD-3). Neurology 2002, 59:1585-1594.
99. Yancopoulou D, Crowther RA, Chakrabarti L, et al.: Tau protein in frontotemporal dementia linked to chromosome 3 (FTD-3). J Neuropathol Exp Neurol 2003, 62:878-882.
100. Skibinski G, Parkinson NJ, Brown JM, et al.: Mutations in the endosomal ESCRTIII-complex subunit CHMP2B in frontotemporal dementia. Nat Genet 2005, 37:806-808.
101. Babst M: A protein's final ESCRT. Traffic 2005, 6:2-9.
102. Cannon A, Baker M, Boeve B, et al.: CHMP2B mutations are not a common cause of frontotemporal lobar degeneration. Neurosci Lett 2006, 398:83-84.
103. Johnson JK, Head E, Kim R, et al.: Clinical and pathological evidence for a frontal variant of Alzheimer disease. Arch Neurol 1999, 56:1233-1239.
104. Klünemann HH, Rogaeva E, Neumann M, et al.: Novel PS1 mutation in a Bavarian kindred with familial Alzheimer disease. Alzheimer Dis Assoc Disord 2004, 18:256-258.
105. Dermaut B, Kumar-Singh S, Engelborghs S, et al.: A novel presenilin 1 mutation associated with Pick's disease but not b-amyloid plaques. Ann Neurol 2004, 55:617-626.
106. Borchelt DR, Thinakaran G, Eckman CB, et al.: Familial Alzheimer's disease-linked presenilin 1 variants elevate Ab1-42/1-40 ratio in vitro and in vivo. Neuron 1996, 17:1005-1013.
107. Duff K, Eckman C, Zehr C, et al.: Increased amyloid-b42(43) in brains of mice expressing mutant presenilin 1. Nature 1996, 383:710-713.
108. Scheuner D, Eckman C, Jensen M, et al.: Secreted amyloid b-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med 1996, 2:864-870.
109. Saura CA, Choi SY, Beglopoulos V, et al.: Loss of presenilin function causes impairments of memory and synaptic plasticity followed by age-dependent neurodegeneration. Neuron 2004, 42:23-36.
110. Baki L, Shioi J, Wen P, et al.: PS1 activates PI3K thus inhibiting GSK-3 activity and tau overphosphorylation: effects of FAD mutations. Embo J 2004, 23:2586-2596.
111. Doglio LE, Kanwar R, Jackson GR, et al.: g-Cleavage-independent functions of presenilin, nicastrin, and Aph-1 regulate cell-junction organization and prevent tau toxicity in vivo. Neuron 2006, 50:359-375.
112. Mahley RW, Weisgraber KH, Huang Y: Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease. Proc Natl Acad Sci USA 2006, 103:5644-5651.
113. Srinivasan R, Davidson Y, Gibbons L, et al.: The apolipoprotein E e4 allele selectively increases the risk of frontotemporal lobar degeneration in males. J Neurol Neurosurg Psychiatry 2006, 77:154-158.
114. Verpillat P, Camuzat A, Hannequin D, et al.: Apolipoprotein E gene in frontotemporal dementia: An association study and meta-analysis. Eur J Hum Genet 2002, 10:399-405.
115. Wilhelmsen KC, Forman MS, Rosen HJ, et al.: 17q-linked frontotemporal dementia-amyotrophic lateral sclerosis without tau mutations with tau and a-synuclein inclusions. Arch Neurol 2004, 61:398-406.
116. Hosler BA, Siddique T, Sapp PC, et al.: Linkage of familial amyotrophic lateral sclerosis with frontotemporal dementia to chromosome 9q21-q22. JAMA 2000, 284:1664-1669.
117. Vance C, Al-Chalabi A, Ruddy D, et al.: Familial amyotrophic lateral sclerosis with frontotemporal dementia is linked to a locus on chromosome 9p13.2-21.3. Brain 2006, 129:868-876.
118. Morita M, Al-Chalabi A, Andersen PM, et al.: A locus on chromosome 9p confers susceptibility to ALS and frontotemporal dementia. Neurology 2006, 66:839-844.
119. Lipton AM, White CL 3rd, Bigio EH: Frontotemporal lobar degeneration with motor neuron disease-type inclusions predominates in 76 cases of frontotemporal degeneration. Acta Neuropathol (Berl) 2004, 108:379-385.
120. Mott RT, Dickson DW, Trojanowski JQ, et al.: Neuropathologic, biochemical, and molecular characterization of the frontotemporal dementias. J Neuropathol Exp Neurol 2005, 64:420-428.